Conditions: Lymphocytic Leukemia, Chronic
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
This single arm study evaluated the bone marrow response, safety, and tolerability of 6 months treatment with Avastin (bevacizumab) monotherapy in patients with chronic lymphocytic leukemia. Patients received 8 cycles (21 days duration) of Avastin monotherapy (15mg/kg) with 6 months of follow-up.

Detailed description:

Arms:
arm 1: Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.

Interventions: intervention 1: Bevacizumab
Intervention descriptions: intervention 1: Bevacizumab was supplied as a sterile liquid in single-use vials.

Protocol document: